CJC-1295, Ipamorelin and Retatrutide: What the Literature Says About Each

Search interest often groups CJC-1295, ipamorelin and retatrutide into a single query, as though they belonged to one research programme. The published literature does not treat them that way. They act on different receptor families, were developed for different indications, and sit at very different stages of clinical investigation. This page summarises what has been reported about each compound individually, and states plainly what has not been studied.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical or treatment question. Nothing here describes a regimen, and no combination of these compounds is described or endorsed.

The three compounds at a glance

CJC-1295: a long-acting GHRH analogue

Mechanism as described in the literature

CJC-1295 is an analogue of growth hormone-releasing hormone modified to bind covalently to circulating albumin, which extends its residence time in plasma. Because it acts upstream at the GHRH receptor, it amplifies the pituitary's own pulsatile growth hormone output rather than supplying exogenous growth hormone. Feedback loops involving somatostatin and IGF-I remain in place, which is the pharmacological rationale investigators have given for studying GHRH analogues.

What was studied

The most frequently referenced human dataset is a 2006 study in healthy adults, in which researchers administered single subcutaneous injections of CJC-1295 at 30, 60 and 125 µg/kg and followed GH and IGF-I concentrations over time (PMID 16352683). The study reported dose-dependent increases in mean growth hormone concentrations of roughly two- to ten-fold for six days or more after a single injection, and increases in IGF-I concentrations of about 1.5- to three-fold that persisted for nine to eleven days. Multiple-dose administration at weekly or biweekly intervals was also examined in the same trial and was reported to sustain elevated IGF-I concentrations, with an estimated half-life on the order of about six to eight days (PMID 16352683).

Two limitations are worth naming. First, that trial measured hormone concentrations, not clinical outcomes such as body composition, injury recovery or longevity endpoints. Elevated IGF-I is a biomarker, and the study did not establish what, if anything, those changes produce clinically. Second, the population was healthy adults studied over weeks, so nothing in the dataset speaks to long-term exposure. The authors reported no serious adverse events in that short-term setting (PMID 16352683), which is not the same as a long-term safety record.

Ipamorelin: a selective growth hormone secretagogue

Mechanism as described in the literature

Ipamorelin is a pentapeptide that acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a) — the receptor for the endogenous hormone ghrelin. Compounds in this class are described as "secretagogues" because they prompt release of stored growth hormone from the pituitary. Ipamorelin has historically been characterised as more selective than earlier secretagogues, in that published pharmacology described comparatively little effect on cortisol and prolactin at GH-releasing exposures. Ipamorelin also has a separate research history in gastrointestinal motility, where GHS-R1a agonism was explored for postoperative ileus.

What the evidence base looks like

Here the page has to be direct: no clinical trial of ipamorelin is cited on this page, because none appears in the verified reference set used to build it. That reflects a real feature of the landscape. Compared with retatrutide, which has multiple registered randomised trials published in high-profile journals, ipamorelin's human literature is thin, older, and largely confined to early pharmacology and an abandoned gastrointestinal development programme. Readers evaluating claims about ipamorelin should notice how often those claims are supported by mechanism talk, animal work or anecdote rather than by controlled human outcome trials.

Because no ipamorelin trial is cited here, this page states no dose, no magnitude of GH response, and no adverse-event rate for ipamorelin. Any source that offers those numbers should be checked against a specific, named, retrievable study.

Why CJC-1295 and ipamorelin are discussed together

The two are often mentioned in the same breath because they act at different receptors within the same axis: one at the GHRH receptor, one at the ghrelin receptor. That complementary pharmacology is the theoretical basis people cite for pairing them. It is worth being precise about what that means — a plausible mechanism is a hypothesis, not a result. The 2006 CJC-1295 study examined CJC-1295 alone (PMID 16352683), and no trial cited here evaluated the two peptides administered together.

Retatrutide: a triple GIP/GLP-1/glucagon receptor agonist

Mechanism as described in the literature

Retatrutide is an investigational single-molecule agonist at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Reviews have described the rationale as combining GLP-1-mediated appetite suppression and glycaemic effects, GIP receptor activity, and glucagon receptor activity thought to contribute to energy expenditure and hepatic fat handling (PMID 39515565, PMID 40563436). This places retatrutide in an entirely different pharmacological family from the growth hormone secretagogues above — it does not act on the GH axis.

Obesity trials

A phase 2 randomised, double-blind, placebo-controlled trial enrolled adults with obesity, or with overweight plus at least one weight-related condition, and assigned them to once-weekly subcutaneous retatrutide or placebo (PMID 37366315). The study reported least-squares mean weight reductions at 48 weeks that reached approximately 24 percent in the highest-dose 12 mg group, compared with about 2 percent with placebo, with dose-dependent results across the 1 mg, 4 mg, 8 mg and 12 mg arms.

Pooled analyses have since summarised the randomised evidence. A systematic review and meta-analysis of randomised controlled trials examined efficacy and safety for obesity treatment and reported significant weight and metabolic changes versus comparators (PMID 40291085). A separate meta-analysis of once-weekly subcutaneous retatrutide examined weight alongside metabolic markers (PMID 39318607), and a Bayesian network meta-analysis compared GLP-1 receptor agonists, dual agonists and retatrutide for weight loss in adults with overweight or obesity (PMID 40685589).

Type 2 diabetes

A phase 2 randomised, double-blind, placebo- and active-controlled parallel-group trial in people with type 2 diabetes compared retatrutide doses with placebo and with dulaglutide 1.5 mg over 36 weeks, and researchers reported dose-dependent reductions in HbA1c and body weight (PMID 37385280). A substudy of that phase 2 programme examined body composition by imaging, reporting changes in fat mass and lean mass among participants with type 2 diabetes (PMID 40609566). More recently, the phase 3 TRANSCEND-T2D-1 trial evaluated efficacy and safety in people with type 2 diabetes and inadequate glycaemic control on diet and exercise alone (PMID 42250575).

Liver and other indications

A randomised phase 2a trial assessed retatrutide in metabolic dysfunction-associated steatotic liver disease, with researchers reporting reductions in liver fat content measured by imaging over the trial period (PMID 38858523). The broader development programme has extended into other obesity-related conditions: the TRIUMPH registrational trials were designed to evaluate retatrutide in obesity, obstructive sleep apnoea and knee osteoarthritis, and a published paper set out their rationale and design (PMID 41090431).

Adverse Events: What Studies Report

For retatrutide, the phase 2 obesity trial reported that the most common adverse events were gastrointestinal — nausea, vomiting, diarrhoea and constipation — that these were mostly mild to moderate, and that they occurred largely during dose escalation (PMID 37366315). The phase 2 type 2 diabetes trial similarly reported dose-related gastrointestinal adverse events as the predominant tolerability issue (PMID 37385280). Meta-analyses that pooled randomised data also examined safety outcomes alongside efficacy (PMID 40291085), and narrative reviews have discussed the safety profile emerging from the phase 2 programme (PMID 40563436).

For CJC-1295, the 2006 healthy-adult study reported no serious adverse events over its short observation window, with the trial designed around hormone pharmacokinetics rather than long-term safety surveillance (PMID 16352683). For ipamorelin, no adverse-event data are cited here, because no ipamorelin trial is included in this page's verified reference set.

The combination question, answered plainly

There is no published randomised trial evaluating CJC-1295 with ipamorelin, or either of them with retatrutide. Every study cited on this page examined a single compound against placebo or an active comparator. The CJC-1295 pharmacology study tested CJC-1295 alone in healthy adults (PMID 16352683); the retatrutide trials tested retatrutide alone against placebo or, in one case, against dulaglutide (PMID 37366315, PMID 37385280).

That absence matters for three reasons:

• Interaction data do not exist. Growth hormone axis stimulation and incretin/glucagon receptor agonism both influence glucose handling, but no trial cited here measured what happens when those two influences are applied simultaneously.
• Safety cannot be inferred additively. A tolerability profile observed for one agent studied alone does not carry over to co-administration, and no cited study addressed that scenario.
• Outcome claims about combinations are unsupported. Any assertion that pairing these compounds produces a particular result is extrapolation from mechanism, not a finding from the literature summarised here.

Regulatory status

Retatrutide is an investigational agent. The trials cited above were conducted within a clinical development programme, including registrational phase 3 studies (PMID 41090431, PMID 42250575), and investigational status means regulators have not completed a full benefit-risk assessment for general use. CJC-1295 and ipamorelin are not approved drug products in the United States; material bearing those names is generally distributed under research-use-only labelling, which is a supply-chain designation and not an indication of clinical quality, purity or safety. This page is educational and is not legal advice; regulatory classifications change and vary by jurisdiction.

How to read claims about these three compounds

1. Check whether a claim names a study. Mechanism descriptions are cheap; retrievable trial citations are not.
2. Check the population. Retatrutide data come from adults with obesity, type 2 diabetes or steatotic liver disease (PMID 37366315, PMID 38858523); CJC-1295 data come from healthy adults in an early pharmacology setting (PMID 16352683).
3. Check the endpoint. Hormone concentrations, imaging-based liver fat, HbA1c and body weight are different classes of outcome and are not interchangeable.
4. Treat combination claims as untested until a trial that actually studied the combination is produced.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (The Lancet Diabetes & Endocrinology, 2025)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (Lancet, 2026)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• The power of three: Retatrutide's role in modern obesity and diabetes therapy (European Journal of Pharmacology, 2024)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings (Baylor University Medical Center), 2025)
• Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials (Metabolism Open, 2024)
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA (Obesity, 2025)